Navigation Links
Antiviral therapy helps children at risk for post-transplant lymphoproliferative disease
Date:7/31/2008

The antiviral drug, valganciclovir, can lower the levels of Epstein-Barr virus in children with liver transplants, according to a new study. About half of young transplant recipients with detectable levels of the virus in their blood responded to a long course of the therapy, with 60 percent maintaining their response when they stopped taking the drug. These findings are in the August issue of Liver Transplantation, a journal by John Wiley & Sons. The article is also available online at Wiley Interscience (www.interscience.wiley.com).

Many pediatric liver recipients become infected with Epstein-Barr virus post-transplant, probably because the latent virus is in lymphocytes in the graft or in blood derivatives. Immunosuppressants taken to control rejection change the children's normal immune response to the virus, leading in some cases to uncontrolled lymphocyte B proliferation. Antiviral therapy is one possible way to address the danger of Epstein-Barr infection in transplant recipients.

Researchers, led by Paloma Jara of Madrid, studied the effects of valganciclovir in 47 pediatric transplant recipients with detectable Epsten-Barr DNA in their blood. They hoped to decrease the risk of post-transplant lymphoproliferative disease (PTLD) by blocking the viral replication that can lead to lymphocyte B proliferation.

After a median 8 months of treatment, EBV-DNA became undetectable in about half of the children who were asymptomatic at the start of the therapy, and no new cases of PTLD developed. In one child, who started the study with suspected PTLD, symptoms worsened over the course of the study. The safety profile was excellent, with no severe adverse events attributed to the drug.

The authors suggest that their results be interpreted with caution as they did not include a control group, and because the short timeframe for follow-up yielded no definitive conclusions about EBV outcomes.

Still, they concluded, "Valganciclovir has been shown safe in the current study and the population of children treated did not develop PTLD, warranting future trials to confirm a positive effect in the management of EBV infection."

In an accompanying editorial, Michael Green and George Mazariegos of the University of Pittsburgh, discuss their experience lowering immune suppression for patients with persistently high EBV loads, instead of using antiviral therapy.

"We have developed a relatively standardized approach to the presence of the high load carrier state which aims to gradually reduce immune suppression while carefully monitoring for any evidence of breakthrough rejection," they report.

"We agree that additional trials of valganciclovir are needed to establish a beneficial effect of this drug," they conclude.


'/>"/>

Contact: Sean Wagner
swagner@wiley.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
2. Antivirals reduce deaths from flu in hospitalized patients
3. Antiviral Wont Improve Bells Palsy Outcome
4. BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy
5. New therapy for HIV treatment
6. Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans
7. Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
8. CSHL scientists correlate enzyme expression levels with chemotherapy drug response
9. D-cycloserine may improve behavioral therapy treatment for anxiety
10. Tx Xchange Launches Web-Based Solution for Physical Therapy and Rehabilitation Providers to Address Demands of Healthcare Consumerism
11. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... with so many different solutions on the market, it is easy to start ... Texas Premier Locksmith offers a complimentary security consultation. , Home Security Hardware ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a leading ... spend management, today announced that Keppel Corporation has selected Apptricity Travel and Expense ... , “We are excited to announce the partnership between Keppel and Apptricity for ...
(Date:2/21/2017)... Okla. (PRWEB) , ... February 21, 2017 , ... ... new Choctaw Nation Regional Medical Clinic in Durant, Oklahoma, on Feb. 21. , ... by clinic tours for community members, clinic employees, the construction team and tribal ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... Doctors ... , CA, directed by Dr. Kendell Mendonca , to its growing network of ... compensation injuries including injuries stemming from car accidents such as whiplash, back pain, neck ...
(Date:2/21/2017)... Fort Worth, TX (PRWEB) , ... February 21, 2017 , ... ... planning assistance to communities in and around Tarrant County, is embarking on a six ... to research cures and treatments for cancer. , Cancer is one of the deadliest ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... SEATTLE , Feb. 22, 2017 ... translational development of novel immune modulating therapies, today ... the a9a10 nicotinic acetylcholine receptor (nAChR), demonstrates robust ... preclinical pain models. The study also establishes the ... the treatment of chronic pain. The findings were ...
(Date:2/22/2017)... , Feb. 22, 2017  Soligenix, Inc. ... Company), a late-stage biopharmaceutical company focused on developing ... there is an unmet medical need, announced today ... been granted a European patent for the treatment ... and methods of treatment of skin conditions, complements ...
(Date:2/21/2017)... -- IBM (NYSE: IBM ) Research has today announced new ... the eye,s retina. The Melbourne based ... recognize abnormalities in retina images, which could in the future ... of patients who may be at risk of eye diseases ... the developed world. The research began in ...
Breaking Medicine Technology: